ASMB Assembly Biosciences (ASMB) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001426800
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
68
13F, latest reported quarter
What the filings say about ASMB
Insiders, 180 days
-$674 net sold
1 seller · 0% of sales under a 10b5-1 plan
Assembly Biosciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ASSEMBLY BIOSCIENCES, INC. insiders sold a net $674 of stock across 66 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 30, 2026.
- The trade is 0.2% of the 14,560 shares held after it.
- No other insider sold within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PFO and PAO Bjorkquist Jeanette M sold about $674 of ASMB on Jun 17, 2026; 68 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 31, 2025.
- The trade is 0.1% of the 11,089 shares held after it.
- 1 other insider sold within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PFO and PAO Bjorkquist Jeanette M sold about $440 of ASMB on Mar 30, 2026; 1 other insider sold within 30 days and 68 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 31, 2025.
- The trade is 2.8% of the 11,105 shares held after it.
- 1 other insider sold within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PFO and PAO Bjorkquist Jeanette M sold about $8.3K of ASMB on Mar 30, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 68 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Mar 31, 2025.
- The trade is 0.0% of the 37,477 shares held after it.
- 1 other insider sold within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Manufacturing Officer White Nicole S sold about $247 of ASMB on Mar 30, 2026; 1 other insider sold within 30 days and 68 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Mar 31, 2025.
- The trade is 0.5% of the 37,486 shares held after it.
- 1 other insider sold within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Manufacturing Officer White Nicole S sold about $5.0K of ASMB on Mar 30, 2026; 1 other insider sold within 30 days and 68 funds added in the latest 13F quarter.66 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$674 over 180 days
more than 64% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
68 funds bought in last quarter
more than 55% of Pharma & Biotech
Revenue
+153.5% year over year
more than 88% of Pharma & Biotech
Margin
-8.5% net margin
more than 65% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
30.8% of the float short (float per yahoo 2026-10-26) · 6.8 days to cover · settled 2026-09-30
more than 82% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ASMB
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-30.1%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ASMB: institutional holders (13F)
13F holdings, latest reported quarter
4,977,089 sh
$136.8M
1,604,590 sh
$44.1M
1,553,748 sh
$42.7M
1,415,000 sh
$38.9M
1,020,410 sh
$28.0M
Congress trades in ASMB
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ASMB planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ASMB mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$339.9K position · as of 2026-07-31
0.7%
Franklin Biotechnology Discovery Fund
$1.0M position · as of 2026-07-31
0.1%
Small Cap Value Fund
$569.6K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$910.5K position · as of 2026-06-30
0.1%
Small Cap Core Fund
$132.1K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$61.3K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
11 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
7
Phase 1
1 active
4
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.5M
$5.5M
$1.3M
+118%
n/a
2024
$1.8M
$2.1M
$895.5K
+1%
n/a
2023
$1.4M
$1.1M
$758.7K
-37%
n/a
2022
$1.8M
$1.3M
$1.6M
-79%
n/a
2021
$2.9M
$1.1M
$1.2M
-61%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $674 sold by insiders over 180 days, 68 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ASMB financials
Revenue growth
+153.5%
XBRL, annual
Net margin
-8.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$74.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ASMB
| FY Dec 2025 | $72.3M |
| FY Dec 2024 | $28.5M |
| FY Dec 2023 | $7.2M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $13.4M |
| Mar 2026 | $8.2M |
| Dec 2025 | $42.5M |
| Sep 2025 | $10.8M |
| Jun 2025 | $9.6M |
| Mar 2025 | $9.4M |
| Dec 2024 | $7.4M |
| Sep 2024 | $6.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-0.1%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ASMB
| FY Dec 2025 | -8.5% |
| FY Dec 2024 | -140.9% |
| FY Dec 2023 | -854.8% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -28.8% |
| Mar 2026 | -110.5% |
| Dec 2025 | +52.0% |
| Sep 2025 | -85.2% |
| Jun 2025 | -105.9% |
| Mar 2025 | -93.6% |
| Dec 2024 | -140.5% |
| Sep 2024 | -140.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$38.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ASMB
| FY Dec 2025 | -$41.2M |
| FY Dec 2024 | -$51.1M |
| FY Dec 2023 | $22.5M |
| FY Dec 2022 | -$84.6M |
| FY Dec 2021 | -$96.5M |
| Jun 2026 | -$15.5M |
| Mar 2026 | -$22.1M |
| Dec 2025 | $14.2M |
| Sep 2025 | -$15.2M |
| Jun 2025 | -$16.8M |
| Mar 2025 | -$23.4M |
| Dec 2024 | -$407.0K |
| Sep 2024 | -$15.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity ASMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt ASMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-0.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ASMB
| FY Dec 2025 | -5.1% |
| FY Dec 2024 | -107.9% |
| FY Dec 2023 | -98.9% |
| FY Dec 2022 | -74.0% |
| FY Dec 2021 | -63.4% |
| Jun 2026 | -0.0% |
| Mar 2026 | -5.7% |
| Dec 2025 | -5.1% |
| Sep 2025 | -36.9% |
| Jun 2025 | -147.6% |
| Mar 2025 | -133.7% |
| Dec 2024 | -107.9% |
| Sep 2024 | -120.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-0.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ASMB
| FY Dec 2025 | -3.2% |
| FY Dec 2024 | -31.4% |
| FY Dec 2023 | -51.3% |
| FY Dec 2022 | -63.6% |
| FY Dec 2021 | -54.8% |
| Jun 2026 | -0.0% |
| Mar 2026 | -3.8% |
| Dec 2025 | -3.2% |
| Sep 2025 | -22.7% |
| Jun 2025 | -39.7% |
| Mar 2025 | -36.5% |
| Dec 2024 | -31.4% |
| Sep 2024 | -53.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital ASMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-5.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ASMB
| FY Dec 2025 | -8.7% |
| FY Dec 2024 | -53.8% |
| FY Dec 2023 | -70.6% |
| FY Dec 2022 | -72.3% |
| FY Dec 2021 | -61.2% |
| Jun 2026 | -5.2% |
| Mar 2026 | -10.7% |
| Dec 2025 | -8.7% |
| Sep 2025 | -35.4% |
| Jun 2025 | -80.9% |
| Mar 2025 | -66.9% |
| Dec 2024 | -53.8% |
| Sep 2024 | -90.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
19.28x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ASMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 26.94x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value ASMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-9.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield ASMB
| FY Dec 2025 | -7.7% |
| FY Dec 2024 | -51.0% |
| FY Dec 2023 | +3.5% |
| FY Dec 2022 | -11.1% |
| FY Dec 2021 | -7.2% |
| Jun 2026 | -8.8% |
| Mar 2026 | -9.0% |
| Dec 2025 | -7.7% |
| Sep 2025 | -28.4% |
| Jun 2025 | -40.4% |
| Mar 2025 | -78.4% |
| Dec 2024 | -51.0% |
| Sep 2024 | +23.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing ASMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $72.3M | $28.5M | $7.2M | $0 |
| Operating income | -$12.1M | -$45.4M | -$64.6M | -$94.1M |
| Net income | -$6.1M | -$40.2M | -$61.2M | -$93.1M |
| EPS (diluted) | -0.55 | -6.69 | -13.38 | -23.08 |
| Operating cash flow | -$41.1M | -$51.1M | $22.7M | -$84.5M |
| Cash | $58.5M | $38.3M | $19.8M | $52.4M |
SEC XBRL, fiscal years, as known on 2026-10-27
ASMB Stock Sonar score 5/7 axes
Find similar shapesCompareASMB ranks highest on growth (88th percentile) and profitability (82nd), and lowest on risk and compliance (8th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ASMB filings, in plain words
Are Assembly Biosciences insiders buying or selling ASMB?
In the 180 days to 2026-10-27, Assembly Biosciences insiders were net sellers, a net $674 across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-27, Assembly Biosciences insiders were net sellers of ASMB, a net $674 across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
